Merck KGaA (ETR:MRK)
Germany
· Delayed Price · Currency is EUR 110.75
-1.95 (-1.73%)
Jul 3, 2025, 5:35 PM CET
Merck KGaA Employees
Merck KGaA had 59,020 employees as of December 31, 2024. The number of employees decreased by 3,888 or -6.18% compared to the previous year.
Employees
59,020
Change (1Y)
-3,888
Growth (1Y)
-6.18%
Revenue / Employee
€340,489
Profits / Employee
€45,013
Market Cap
49.00B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 59,020 | -3,888 | -6.18% |
| Dec 31, 2023 | 62,908 | -1,324 | -2.06% |
| Dec 31, 2022 | 64,232 | 3,898 | 6.46% |
| Dec 31, 2021 | 60,334 | 2,207 | 3.80% |
| Dec 31, 2020 | 58,127 | 1,056 | 1.85% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Healthineers AG | 72,000 |
| Bayer Aktiengesellschaft | 91,864 |
| Fresenius SE & Co. KGaA | 176,486 |
| Fresenius Medical Care AG | 111,513 |
| Sartorius Aktiengesellschaft | 13,528 |
| Carl Zeiss Meditec AG | 5,730 |
| Fielmann Group AG | 24,363 |
| SCHOTT Pharma AG & Co. KGaA | 4,690 |
Merck KGaA News
- 2 days ago - Merck KGaA, Darmstadt, Germany Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business - Business Wire
- 14 days ago - Merck Foundation Chairman, CEO, and 14 First Ladies Inaugurate the 7th Edition of Merck Foundation First Ladies Initiative – MFFLI Summit in Dubai - Business Upturn
- 15 days ago - MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant - Financial Post
- 20 days ago - EQS-PVR: Merck KGaA: Correction of a release from 05/06/2025 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 24 days ago - China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Benzinga
- 24 days ago - China's Center for Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Business Wire
- 24 days ago - China's Center for Drug Evaluation Accepts Merck's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor - Business Wire
- 4 weeks ago - EQS-PVR: Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online